94 related articles for article (PubMed ID: 19400213)
1. Semi-synthetic strategies to obtain glucosylated MOG to identify antibodies as biomarkers in multiple sclerosis disease.
Gori F; Mulinacci B; Bonchi E; Chelli M; Lolli F; Papini AM; Rovero P
Adv Exp Med Biol; 2009; 611():327-8. PubMed ID: 19400213
[No Abstract] [Full Text] [Related]
2. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
Lolli F; Rovero P; Chelli M; Papini AM
Neurology; 2005 Sep; 65(5):781-2; author reply 781-2. PubMed ID: 16157927
[No Abstract] [Full Text] [Related]
3. A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases.
Mazzucco S; Matà S; Vergelli M; Fioresi R; Nardi E; Mazzanti B; Chelli M; Lolli F; Ginanneschi M; Pinto F; Massacesi L; Papini AM
Bioorg Med Chem Lett; 1999 Jan; 9(2):167-72. PubMed ID: 10021921
[TBL] [Abstract][Full Text] [Related]
4. Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.
Reder AT; Oger JJ
Neurology; 2004 Jun; 62(11):1922-3. PubMed ID: 15184588
[No Abstract] [Full Text] [Related]
5. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
Reindl M; Linington C; Brehm U; Egg R; Dilitz E; Deisenhammer F; Poewe W; Berger T
Brain; 1999 Nov; 122 ( Pt 11)():2047-56. PubMed ID: 10545390
[TBL] [Abstract][Full Text] [Related]
6. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations.
Pittock SJ; Reindl M; Achenbach S; Berger T; Bruck W; Konig F; Morales Y; Lassmann H; Bryant S; Moore SB; Keegan BM; Lucchinetti CF
Mult Scler; 2007 Jan; 13(1):7-16. PubMed ID: 17294606
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis.
Karni A; Bakimer-Kleiner R; Abramsky O; Ben-Nun A
Arch Neurol; 1999 Mar; 56(3):311-5. PubMed ID: 10190821
[TBL] [Abstract][Full Text] [Related]
8. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.
Berger T; Reindl M
J Neural Transm Suppl; 2000; (60):351-60. PubMed ID: 11205153
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients.
Markovic M; Trajkovic V; Drulovic J; Mesaros S; Stojsavljevic N; Dujmovic I; Mostarica Stojkovic M
J Neurol Sci; 2003 Jul; 211(1-2):67-73. PubMed ID: 12767500
[TBL] [Abstract][Full Text] [Related]
10. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.
Mantegazza R; Cristaldini P; Bernasconi P; Baggi F; Pedotti R; Piccini I; Mascoli N; La Mantia L; Antozzi C; Simoncini O; Cornelio F; Milanese C
Int Immunol; 2004 Apr; 16(4):559-65. PubMed ID: 15039386
[TBL] [Abstract][Full Text] [Related]
11. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis.
Clements CS; Reid HH; Beddoe T; Tynan FE; Perugini MA; Johns TG; Bernard CC; Rossjohn J
Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11059-64. PubMed ID: 12960396
[TBL] [Abstract][Full Text] [Related]
12. Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis.
Kennel De March A; De Bouwerie M; Kolopp-Sarda MN; Faure GC; Béné MC; Bernard CC
J Neuroimmunol; 2003 Feb; 135(1-2):117-25. PubMed ID: 12576231
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.
Lalive PH; Menge T; Delarasse C; Della Gaspera B; Pham-Dinh D; Villoslada P; von Büdingen HC; Genain CP
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2280-5. PubMed ID: 16461459
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls.
Xiao BG; Linington C; Link H
J Neuroimmunol; 1991 Feb; 31(2):91-6. PubMed ID: 1991822
[TBL] [Abstract][Full Text] [Related]
15. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells.
Forsthuber TG; Shive CL; Wienhold W; de Graaf K; Spack EG; Sublett R; Melms A; Kort J; Racke MK; Weissert R
J Immunol; 2001 Dec; 167(12):7119-25. PubMed ID: 11739534
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.
Marta CB; Oliver AR; Sweet RA; Pfeiffer SE; Ruddle NH
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13992-7. PubMed ID: 16172404
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
Gaertner S; de Graaf KL; Greve B; Weissert R
Neurology; 2004 Dec; 63(12):2381-3. PubMed ID: 15623705
[TBL] [Abstract][Full Text] [Related]
18. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis.
Egg R; Reindl M; Deisenhammer F; Linington C; Berger T
Mult Scler; 2001 Oct; 7(5):285-9. PubMed ID: 11724443
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy.
Angelucci F; Mirabella M; Frisullo G; Caggiula M; Tonali PA; Batocchi AP
Dis Markers; 2005; 21(2):49-55. PubMed ID: 15920290
[TBL] [Abstract][Full Text] [Related]
20. Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis.
Carotenuto A; D'Ursi AM; Nardi E; Papini AM; Rovero P
J Med Chem; 2001 Jul; 44(14):2378-81. PubMed ID: 11428934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
